Replies to post #105802 on Biotech Values

[oc631]

Not true with respect to having their pick of PIs in development. As discussed on here before (#msg-55255861), Roche had an exclusivity deal with ITMN regarding HCV PIs and had to opt out of this arrangement before it could license an HCV PI from another company.

That agreement only pertained to RG7128.